Table 1.
Demographics, comorbidities, disease severity for the derivation cohort
| Variable | All patients (N = 172) |
Rapid Recovery (N = 114) |
CCI (N = 41) |
Early death (N = 17) |
p Value+ | |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age, in years* | 61 (51, 70) | 60 (49, 69) | 64 (56, 73) | 63 (57, 74) | 0.129a | |
| Gender, male | 99 (58) | 63 (55) | 25 (61) | 11 (65) | 0.671b | |
| Race, White | 123 (72) | 78 (68) | 33 (80) | 12 (71) | 0.364c | |
| Black | 47 (27) | 35 (31) | 7 (17) | 5 (29) | ||
| Other | 2 (1) | 1 (1) | 1 (2) | 0 (0) | ||
| Charlson comorbidity index | ||||||
| Charlson score* | 3 (2, 5) | 3 (1, 5) | 4 (2, 6) | 4 (3, 6) | 0.019a | |
| Medications | ||||||
| Statin use | 62 (36) | 41 (37) | 13 (32) | 8 (47) | 0.542b | |
| Initial biomarkers and organ failure | ||||||
| 1st serum lactate (mmol/dL)* | 2.1 (1.5, 3.2) | 2 (1.5, 3) | 1.70 (1.1, 2.9) | 3.8 (2.8, 5) | < 0.001a | |
| 2nd serum lactate (mmol/dL)* | 1.7 (1.1, 2.8) | 1.5 (1.1, 2.4) | 1.5 (1.1, 2.5) | 4.1 (3.1, 8.0) | < 0.001a | |
| Procalcitonin** | 8.06 (2.3, 34.1) | 13.3 (1.5, 27.1) | 4.1 (1.8, 51.6) | 7.6 (3.2, 100) | 0.750a | |
| Enrollment SOFA score* | 5 (3, 8) | 4 (2, 6) | 7 (5, 10) | 10 (9, 13) | < 0.001a | |
| Apache II score* | 15 (10, 20) | 12 (8, 17) | 19 (15, 25) | 21 (18, 27) | < 0.001a | |
Bold values are significant after Bonferroni correction for multiple comparisons
Data is count (percentage), unless otherwise specified by *median (1st quartile, 3rd quartile); **n = 63; aWilcoxon rank-sum test; bPearson Chi-square test; cFisher’s exact test; +after Bonferroni adjustment for multiple tests, significant if < 0.002 (0.05/47 tests). Comparisons are bivariate between rapid recovery vs. CCI or early death